


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of formula (I),



(I)

or a pharmaceutically acceptable derivative salt thereof, wherein:

Het represents is 2-pyridinyl or 2-pyrimidinyl;

R¹ represents is H, C₁₋₃ alkyl or a nitrogen-containing heterocyclic ring having 5 or 6 ring atoms;

R² represents is H, benzyl or C₁₋₃ alkyl; and

R³ represents is H, methyl, methoxy or chloro.

2. (Currently amended) A The compound according to claim 1, or a pharmaceutically acceptable derivative salt thereof, wherein Het represents is 2-pyridinyl.

3. (Currently amended) A The compound according to claim 1, or a pharmaceutically acceptable derivative salt thereof, wherein R¹ represents is 1,2,3-triazolyl.

4. (Currently amended) A The compound according to claim 1, or a pharmaceutically acceptable derivative salt thereof, wherein R² represents is H or methyl.

5. (Currently amended) A The compound according to claim 1, or a pharmaceutically acceptable derivative salt thereof, wherein R³ represents is chloro.

6. (Currently amended) A The compound as claimed in claim 1, or a pharmaceutically acceptable derivative salt thereof, wherein at least one of R¹, R² and R³ represents is a group other than H.

7. (Currently amended) A compound as claimed in claim 1, or a pharmaceutically acceptable derivative salt thereof, wherein R¹ represents is 1,2,3-triazolyl and/or and R³ represents is chloro.

8. (Currently amended) A ~~compound according to claim 1, selected from~~ 2-{4-[4-(2-Ethyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine; 2-{4-[5-Methyl-4-(2-propyl-phenyl)-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine; 2-{4-[4-(2-Isopropyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine 4-(5-Morpholin-4-ylmethyl-4-phenyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-(5-Butyl-4-phenyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-(4-Phenyl-5-piperidin-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-(5-Methyl-4-phenyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-[4-(4-Methoxy-2-methyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-[4-(4-Chloro-2-methyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-(5-Methyl-4-o-tolyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-[4-(4-Chloro-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-[4-(4-Methoxy-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-[4-(4-Methoxy-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; 4-(4-o-Tolyl-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;

4-[4-(4-Chloro-2-methyl-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-(4-Phenyl-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-(5-Methyl-4-p-tolyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
4-[4-(2,4-Dimethyl-phenyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; or
4-[4-(4-Chloro-2-methyl-phenyl)-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl; and
or a pharmaceutically acceptable derivatives salt thereof.

9. (Canceled)

10. (Currently amended) A method of treating treatment of a disorder selected from ~~anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia, primary dysmenorrhea, secondary dysmenorrhea, premature ejaculation, or rheumatoid arthritis~~ premature (preterm) labor and Raynaud's disease, comprising administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable derivative salt thereof, to a patient suffering from such a disorder.

11. (Currently amended) A The method according to claim 10 wherein the disorder is ~~dysmenorrhoea (primary or secondary) primary dysmenorrhea or secondary dysmenorrhea.~~

12. (Currently amended) A The method according to claim 11 wherein the disorder is primary dysmenorrhoea dysmenorrhea.

13.-15. (Canceled)

16. (Currently amended) A pharmaceutical formulation including composition comprising a compound according to claim 1 or a pharmaceutically acceptable derivative salt thereof, together with a pharmaceutically acceptable excipients, excipient, diluent or carrier; carrier.

17. (Currently amended) A pharmaceutical product containing a V1a antagonist composition comprising a compound according to claim 1 or a pharmaceutically acceptable derivative salt thereof in combination with a compound selected from (a) an oral contraceptive, (b) a PDE5 inhibitor, (c) an NO donor, (d) L-arginine, or (e) a COX inhibitor, together with a pharmaceutically acceptable acceptable excipient, carrier or diluent as a combined preparation for simultaneous, separate or sequential use in the treatment of dysmenorrhoea.